Key clinical point: Selective internal radiation therapy (SIRT) with 90Y demonstrated favorable survival benefits in patients with breast cancer (BC) and hepatic metastasis, particularly in those with low liver tumor burden and without extrahepatic metastasis.
Major finding: Postembolization median survival time (MST) was 9.8 months, with MST being significantly higher in patients with <25% vs >25% hepatic metastatic burden (10.5 vs 6.8 months; P < .0001) and localized vs additional hepatic metastasis (15.0 vs 5.3 months; P < .0001). None of the adverse events were life-threatening.
Study details : Findings are from a meta-analysis of 24 studies including 412 patients with metastatic BC and hepatic metastasis who had received SIRT.
Disclosures: This study was funded by the Natural Science Foundation of Shandong Province, China. The authors declared no conflicts of interest.
Source: Liu C et al. Selective internal radiation therapy of metastatic breast cancer to the liver: A meta-analysis. Front Oncol. 2022;12:887653 (Nov 24). Doi: 10.3389/fonc.2022.887653